SPK-FIX: Phase I/II data

Top-line data from the first 3 severe hemophilia B patients in an open-label, dose-escalation, U.S. Phase I/II trial showed that a single dose of 5x10^11 vg/kg IV SPK-9001 led to “AAV-mediated Factor ...